A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight
NCT ID: NCT00542009
Last Updated: 2012-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
252 participants
INTERVENTIONAL
2007-12-31
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CE-326,597 100 mg QD
CE-326,597 100 mg QD
Administered orally, once daily with morning meal for duration of trial (84 days).
CE-326,597 50 mg QD
CE-326,597 50 mg QD
Administered orally, once daily with morning meal for duration of trial (84 days).
CE-326,597 25 mg QD
CE-326,597 25 mg QD
Administered orally, once daily with morning meal for duration of trial (84 days).
Placebo
Placebo
Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
CE-326,597 5mg QD
CE-326,597 5mg QD
Administered orally, once daily with morning meal for duration of trial (84 days).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CE-326,597 100 mg QD
Administered orally, once daily with morning meal for duration of trial (84 days).
CE-326,597 50 mg QD
Administered orally, once daily with morning meal for duration of trial (84 days).
CE-326,597 25 mg QD
Administered orally, once daily with morning meal for duration of trial (84 days).
Placebo
Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
CE-326,597 5mg QD
Administered orally, once daily with morning meal for duration of trial (84 days).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
National City, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Ocala, Florida, United States
Pfizer Investigational Site
West Palm Beach, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Conyers, Georgia, United States
Pfizer Investigational Site
Honolulu, Hawaii, United States
Pfizer Investigational Site
Idaho Falls, Idaho, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Overland Park, Kansas, United States
Pfizer Investigational Site
Bethesda, Maryland, United States
Pfizer Investigational Site
Chaska, Minnesota, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Jackson, Mississippi, United States
Pfizer Investigational Site
Henderson, Nevada, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Fargo, North Dakota, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Lansdale, Pennsylvania, United States
Pfizer Investigational Site
Rapid City, South Dakota, United States
Pfizer Investigational Site
Beaumont, Texas, United States
Pfizer Investigational Site
Beaumont, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Pleven, , Bulgaria
Pfizer Investigational Site
Sofia, , Bulgaria
Pfizer Investigational Site
Sofia, , Bulgaria
Pfizer Investigational Site
Stara Zagora, , Bulgaria
Pfizer Investigational Site
Coquitlam, British Columbia, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Laval, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Indore, Madhya Pradesh, India
Pfizer Investigational Site
Nagpur, Maharashtra, India
Pfizer Investigational Site
Nashik, Maharashtra, India
Pfizer Investigational Site
Ladrón de Guevara, Guadalajara, Jalisco, Mexico
Pfizer Investigational Site
Guadalajara, Jalisco, Mexico
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico
Pfizer Investigational Site
Ponce, , Puerto Rico
Pfizer Investigational Site
San Juan, , Puerto Rico
Pfizer Investigational Site
Tao Baja, , Puerto Rico
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Santiago de Compostela, La Coruña, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Seville, Sevilla, Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A7211005
Identifier Type: -
Identifier Source: org_study_id